Featured Research Search Results
Evaluating the Benefit of Adding ART6043 to Olaparib for HER2-Negative Metastatic or Advanced Breast Cancer and a BRCA Mutation (POLKA)
Clinicaltrials.gov identifier:
NCT05898399
Treatment
Metastatic breast cancer treatment study
Phase 1/2
A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone or Darolutamide (TALENT)
Clinicaltrials.gov identifier:
NCT06844383
Treatment
Study for metastatic castration-resistant prostate cancer with an HRR mutation
Phase 2
ERADICATE: Hormone and Targeted Therapy for HR+/HER2-Low Advanced Breast Cancer
Clinicaltrials.gov identifier:
NCT07198724
Treatment
Study of hormone and targeted therapy for advanced breast cancer
Phase 1/2
Using a Computer Model to Identify Treatment Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast)
Clinicaltrials.gov identifier:
NCT07067138
Treatment
Treatment study for people with metastatic breast cancer
Treating Advanced MSI-High or dMMR Cancers Using the Targeted Therapy MOMA-341 Given Alone or In Combination with Standard Therapies
Clinicaltrials.gov identifier:
NCT06974110
Treatment
Treatment study for people with advanced or metastatic cancers
Phase 1
A New Drug, DT2216, Combined With Paclitaxel for Recurrent Platinum-Resistant Ovarian Cancer
Clinicaltrials.gov identifier:
NCT06964009
Treatment
Treatment study for people with recurrent platinum-resistant ovarian cancer
Phase 1
Comparing Treatment with Sacituzumab Govitecan and Bevacizumab to Chemotherapy and Bevacizumab for Recurrent Ovarian Cancer After PARP Inhibitor Maintenance Therapy
Clinicaltrials.gov identifier:
NCT07504588
Treatment
Study for platinum-sensitive ovarian cancer that has progressed after PARP inhibitor
Phase 2
Study of Dostarlimab Immunotherapy in People with Mismatch Repair-Deficient Endometrial Cancer Who Wish to Preserve Fertility
Clinicaltrials.gov identifier:
NCT04165772
Treatment
Treatment study for people with MSI-H or dMMR early-stage endometrial cancer
Phase 2
A Study to Learn About the Study Medicine Called PF-07248144 in Combination with Fulvestrant in People with HR-positive, HER2-negative Advanced or Metastatic Breast Cancer who Progressed After a Prior Line of Treatment
Clinicaltrials.gov identifier:
NCT07062965
Treatment
Study for adults with advanced/metastatic HR-positive, HER2-negative breast cancer who have progressed from prior treatment
Phase 3
Comparing Shorter vs. Standard Radiation for High-Risk Prostate Cancer (High Five)
Clinicaltrials.gov identifier:
NCT05946213
Treatment
Treatment study for high-risk prostate cancer
Phase 3
Testing the Drug CX-5461 for Treating Metastatic Solid Tumors
Clinicaltrials.gov identifier:
NCT06606990
Treatment
Phase 1 study for treatment of advanced solid tumors
Phase 1
Using the Drug Daraxonrasib in Surgically Removed Pancreatic Cancer (RASolute 304)
Clinicaltrials.gov identifier:
NCT07252232
Treatment
Study for pancreatic cancer treatment after surgery and chemotherapy
Phase 3
Comparing Daraxonrasib With or Without Chemotherapy to Chemotherapy Alone for First-Line Treatment of Metastatic Pancreatic Cancer (Rasolute 303)
Clinicaltrials.gov identifier:
NCT07491445
Treatment
Study for First-Line Treatment of Metastatic Pancreatic Cancer
Phase 3
Testing a Targeted Therapy ETX-19477 to Treat Advanced Solid Tumors in People with a BRCA2 Mutation (ERADIC8)
Clinicaltrials.gov identifier:
NCT06395519
Treatment
Treatment study for people with advanced breast, colorectal, endometrial, ovarian or pancreatic cancer
Phase 1/2
Study of a New Oral Medication, Daraxonrasib After Surgery to Help Prevent Pancreatic Cancer from Returning
Clinicaltrials.gov identifier:
NCT07252232
Treatment
Phase 3 treatment trial for pancreatic cancer that was removed by surgery
Phase 3
Comparing Two Vaccine Treatments With Immunotherapy for Pancreatic Cancer Before and After Surgery
Clinicaltrials.gov identifier:
NCT06782932
Treatment
Treatment study for newly diagnosed pancreatic cancer that can be removed with surgery and who have not yet received treatment
Phase 1/2
Comparing an Investigational Targeted Drug AZD5335 to Standard Treatments in People With Platinum‑Resistant Ovarian Cancer (TREVI‑OC‑01)
Clinicaltrials.gov identifier:
NCT07218809
Treatment
Treatment study for platinum-resistant ovarian cancer
Phase 3
Using a Blood Test to Detect Early Cancer Recurrence After Treatment (ORACLE)
Clinicaltrials.gov identifier:
NCT05059444
Treatment
Post-treatment study to monitor for recurrence